How to Determine IPO Offering Size: Finding the Optimal Balance Between Proceeds and Market Cap

The decision to list on the NYSE or Nasdaq in 2025 is no longer a simple equation of capital raised versus dilution. A structural shift in the US primary market, driven by the SEC’s amended Rule 3b-4 and the concurrent tightening of SPAC de-SPAC valuations, has fundamentally altered the calculus for determining the optimal IPO offering size. Since Q1 2024, the average US IPO has seen a 23% compression in the ratio of proceeds to post-money market capitalisation, according to data compiled by Renaissance Capital, forcing issuers and their sponsors to recalibrate the traditional 10-15% free float target. For Hong Kong-headquartered companies and cross-border issuers navigating the US listing desk, the central question is no longer just “how much can we raise,” but “how does the offering size lock in valuation stability, liquidity, and institutional credibility in a market where 40% of 2024 IPOs traded below their offer price on day one?”

The Changing Regulatory and Market Backdrop for US IPO Sizing

The SEC’s final adoption of Rule 3b-4 in March 2024, which redefined “accelerated filer” and “large accelerated filer” thresholds, has direct implications for an issuer’s ongoing compliance costs and, by extension, the minimum viable offering size. Under the new thresholds, an issuer with a public float below USD 250 million is no longer classified as an accelerated filer, removing the requirement for an auditor attestation on internal controls under Section 404(b) of the Sarbanes-Oxley Act. For a company targeting a USD 500 million market cap at listing, this means a free float of exactly USD 250 million—50% of the post-money capitalisation—triggers a materially higher annual audit and compliance burden, estimated by the Center for Audit Quality at USD 1.2-2.8 million per year. This regulatory pivot forces issuers to either cap their offering size below the threshold or accept the incremental cost as a price of liquidity.

Simultaneously, the SPAC market’s recalibration has compressed the range of viable offering sizes. In 2023, the average de-SPAC transaction involved a target company valuation of USD 1.2 billion with a trust of USD 250 million, yielding a 20.8% implied cash-to-valuation ratio. By Q2 2025, that ratio has fallen to 14.5%, per SPAC Research, as sponsors struggle to secure PIPE commitments. For a traditional IPO, this creates a ceiling: if a SPAC can offer a comparable valuation with less dilution, a traditional IPO must deliver superior liquidity and after-market support to justify a larger offering size. The market’s message is clear—over-raising in a traditional IPO no longer commands a premium.

Core Determinants of Offering Size: From Free Float to Price Stabilisation

Free Float Requirements and Institutional Demand

The NYSE and Nasdaq each impose minimum public float requirements, but the real constraint is institutional appetite. The NYSE Listed Company Manual Section 102.01B requires a minimum of 1.1 million publicly held shares with a market value of USD 40 million for a Main Board listing. Nasdaq Listing Rule 5405(a)(2) demands 1.25 million publicly held shares for the Global Select Market. These are floor requirements, not targets. The effective minimum for a liquid, institutional-grade listing is a free float of 20-25% of the post-money market cap, based on the observed distribution of 2024 US IPOs with market caps between USD 500 million and USD 2 billion, as tracked by Dealogic.

For a Hong Kong-based issuer, the free float decision intersects with the HKEX’s own requirements under Listing Rule 8.08(1), which mandates a minimum public float of 25% for Main Board listings. A company dual-listing in Hong Kong and New York must reconcile these thresholds. The practical solution adopted by 12 of the 18 dual-listed companies in 2024, per HKEX data, was to set the US offering at 10-15% of the global float and the Hong Kong tranche at the remaining 10-15%, ensuring each venue meets its respective minimum without exceeding a 30% total dilution.

Price Stabilisation and the Greenshoe Mechanism

The over-allotment option, or greenshoe, is a critical lever in sizing the offering. The standard greenshoe is 15% of the base deal size, as codified in underwriting agreements under FINRA Rule 5130. For an issuer targeting a USD 200 million base offering, the greenshoe adds USD 30 million of potential proceeds, bringing the maximum to USD 230 million. The greenshoe’s function is not merely to raise additional capital but to stabilise the stock price during the first 30 days post-listing. Data from the SEC’s Office of the Investor Advocate shows that IPOs with a fully exercised greenshoe in 2024 experienced an average price decline of only 2.3% from the offer price in the first 20 trading days, compared to 7.1% for those where the greenshoe was not exercised.

Issuers must decide whether to size the base offering such that the greenshoe, if fully exercised, does not push the free float above the 25% threshold that would trigger accelerated filer status under the new Rule 3b-4. For a company with a USD 1 billion target market cap, a base offering of USD 150 million (15% float) plus a USD 22.5 million greenshoe yields a total float of 17.25%. A base offering of USD 200 million (20% float) plus a USD 30 million greenshoe yields 23%—still below the 25% accelerated filer trigger, but leaving no room for error. The optimal structure, based on 2024 filings, is to set the base offering at 12-15% of post-money market cap, preserving greenshoe capacity without crossing the regulatory line.

Sector-Specific Sizing: Technology, Biotech, and SPAC De-SPAC Dynamics

Technology Issuers: Growth Premium vs. Dilution Sensitivity

Technology issuers in 2025 face a unique tension: the market rewards high-growth stories with valuation multiples, but penalises excessive dilution. For a SaaS company with a USD 2 billion pre-money valuation and 3x revenue growth, the optimal offering size in Q2 2025 is between USD 200 million and USD 300 million, representing a 10-15% free float. This range is derived from the median of 14 US-listed tech IPOs in the first half of 2025, as reported by PitchBook. Below USD 200 million, the offering lacks the liquidity to attract institutional investors; above USD 300 million, the dilution compresses the post-money valuation and signals a capital-intensive business model that may not sustain its growth premium.

The greenshoe structure for tech issuers often includes a secondary component. In a typical tech IPO, 20-30% of the shares offered come from existing shareholders via a secondary sale, allowing the company to raise primary capital for growth while providing liquidity for early investors. The SEC’s Rule 144 holding period for affiliates remains six months, but the IPO itself serves as a liquidity event that resets the clock. For a Hong Kong-based tech company with a Cayman Islands holding structure, the secondary component must be structured to avoid triggering the PRC’s Circular 37 filing requirements for offshore asset transfers, a consideration that adds legal complexity but does not change the sizing mathematics.

Biotech Issuers: The Cash Runway Constraint

Biotech IPOs are distinct in that the offering size is primarily a function of cash runway, not valuation. A pre-revenue biotech company must raise enough capital to fund operations for 18-24 months post-listing, as clinical-stage companies rarely achieve positive cash flow within that window. The median biotech IPO in 2024 raised USD 85 million, according to BioPharma Dive, with a post-money market cap of USD 350 million, yielding a 24.3% free float. The cash runway rule of thumb is that the offering size should equal 2.5x the company’s annual burn rate. For a company with a USD 30 million annual burn, the minimum offering is USD 75 million, leaving a USD 10 million buffer for the greenshoe.

The SEC’s accelerated filer threshold is less relevant for biotech issuers, as most fall below the USD 250 million public float threshold. However, the Nasdaq’s continued listing requirements under Listing Rule 5450(b)(2) demand a minimum market value of publicly held shares of USD 15 million, which for a USD 350 million market cap company translates to a USD 15 million free float—easily met by a USD 85 million offering. The real constraint is the underwriting spread, which for biotech IPOs averages 7% of gross proceeds, per Dealogic. For a USD 75 million offering, the spread is USD 5.25 million, leaving net proceeds of USD 69.75 million—a figure that must be disclosed in the prospectus under Item 11 of Form S-1.

SPAC De-SPAC: Sizing the Trust and PIPE

For a company considering a SPAC merger as an alternative to a traditional IPO, the offering size is effectively the sum of the trust cash and any concurrent PIPE investment. The median de-SPAC in 2024 had a trust of USD 187 million and a PIPE of USD 63 million, per SPAC Research, for a total of USD 250 million. The target company’s valuation must be sized such that the trust cash represents 15-20% of the pro-forma enterprise value. For a company with a USD 1.5 billion enterprise value, the trust must be at least USD 225 million to meet this threshold. If the trust is smaller, the PIPE must fill the gap, but PIPE investors in 2025 demand a 15-20% discount to the de-SPAC valuation, effectively reducing the net proceeds.

The SEC’s proposed amendments to the SPAC rules, released in March 2024, would require that the target company be deemed a “co-registrant” under the Securities Act, exposing it to liability for forward-looking statements. This regulatory shift has compressed the premium that SPACs can offer. In Q2 2025, the average de-SPAC valuation was 1.2x the target’s last private round, compared to 1.5x in 2022, per SPAC Analytics. For an issuer choosing between a traditional IPO and a SPAC, the offering size must account for this valuation compression. A traditional IPO at 1.5x revenue may yield a higher valuation than a SPAC at 1.2x, even if the SPAC offers a lower dilution.

Practical Framework for Determining the Optimal Size

Step One: Define the Minimum Viable Float

The first calculation is the minimum public float required to meet exchange listing standards and institutional liquidity expectations. For a company targeting a USD 1 billion market cap, the minimum float is 20% or USD 200 million. This figure must be adjusted for the greenshoe: a base offering of USD 174 million plus a USD 26 million greenshoe (15% of base) yields a total of USD 200 million. This structure ensures that even if the greenshoe is not exercised, the base offering of USD 174 million (17.4% float) is sufficient for liquidity, while the greenshoe provides stabilisation capacity.

Step Two: Assess the Accelerated Filer Threshold

If the post-IPO public float exceeds USD 250 million, the issuer becomes an accelerated filer, triggering Section 404(b) auditor attestation. For a USD 1 billion market cap company, a float of 25% or USD 250 million is the exact threshold. To avoid crossing it, the base offering plus greenshoe should not exceed USD 250 million. The optimal structure is a base of USD 217 million (21.7% float) plus a USD 33 million greenshoe, for a total of USD 250 million. This structure maximises proceeds while staying within the non-accelerated filer classification, saving an estimated USD 1.5-2.0 million in annual compliance costs.

Step Three: Validate Against Sector Benchmarks

The final step is to compare the proposed offering size against sector-specific medians. For a tech issuer, the offering size should be 10-15% of post-money market cap; for a biotech issuer, 2.5x annual burn rate; for a SPAC, 15-20% of pro-forma enterprise value. If the calculated size deviates by more than 20% from the sector median, the issuer should revisit the valuation assumption or consider a dual-tranche structure that separates primary and secondary components.

Actionable Takeaways

1. Set the base offering at 12-15% of post-money market cap to preserve greenshoe capacity while staying below the USD 250 million accelerated filer threshold under the SEC’s amended Rule 3b-4.
2. Structure the greenshoe at exactly 15% of the base offering, as codified in FINRA Rule 5130, to provide price stabilisation without exceeding the target free float.
3. For biotech issuers, size the offering at 2.5x the annual burn rate, with a minimum of USD 75 million to cover the 18-24 month cash runway required by institutional investors.
4. In a SPAC de-SPAC, ensure the trust cash plus PIPE equals at least 15% of the pro-forma enterprise value, and negotiate a PIPE discount of no more than 15% to avoid excessive dilution.
5. Validate the final offering size against the sector median for the most recent 12-month period, using data from Dealogic or PitchBook, and adjust the valuation if the deviation exceeds 20%.